ClinicalTrials.gg
RecruitingNCT07794514Updated Nov 17, 2026

Belumosudil Versus Ruxolitinib for Steroid-Refractory or Breakthrough Hepatic cGVHD

An interventional study of Ruxolitinib treatment and Belumosudil treatment in Hematopoietic Stem Cell Transplantation (HSCT), cGVHD and Hepatic cGVHD, sponsored by First Affiliated Hospital of Zhejiang University. Recruiting at 1 site in China. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by First Affiliated Hospital of Zhejiang University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
170
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Study summary

This prospective, randomized, open-label, multicenter trial aims to compare second-line treatment strategies for hepatic cGVHD after allo-HSCT. Ruxolitinib and belumosudil are both effective for cGVHD, but no head-to-head comparison specifically in hepatic cGVHD has been reported. Two cohorts are enrolled: Cohort 1 comprises patients with steroid-refractory hepatic cGVHD without prior ruxolitinib or belumosudil exposure, randomized to receive either agent. Cohort 2 includes patients who develop new-onset hepatic cGVHD after ≥4 weeks of therapy with ruxolitinib or belumosudil for other-organ cGVHD (stable for ≥2 weeks), or patients with non-response/progression on either agent for hepatic cGVHD; these patients will be switched to the opposite drug. Key questions include: • In steroid-refractory hepatic cGVHD, does 24-week hepatic overall response rate differ between belumosudil and ruxolitinib? • What is the hepatic response rate after drug switching in Cohort 2? • How do the two agents compare in safety and tolerability for hepatic cGVHD? • What are their impacts on corticosteroid tapering, failure-free survival, and long-term outcomes? Participants will: • Receive assigned treatment per cohort and randomization • Undergo regular efficacy/safety monitoring, including hepatic cGVHD scoring, liver function tests, and adverse event recording • Provide peripheral blood samples at baseline and multiple on-treatment time points for exploratory biomarker analysis • Complete 24-week primary efficacy assessment with follow-up until progression or discontinuation Primary endpoint is 24-week hepatic overall response rate (CR+PR, per 2014 NIH cGVHD criteria). Secondary endpoints include duration of response, failure-free survival, corticosteroid tapering rate, safety (AE/SAE incidence), liver function improvement, and patient-reported outcomes. This head-to-head comparison will provide high-level evidence for selecting second-line and beyond therapies for hepatic cGVHD.

02

Conditions studied

  • Hematopoietic Stem Cell Transplantation (HSCT)
  • cGVHD
  • Hepatic cGVHD
  • Belumosudil
  • Ruxolitinib

Keywords

  • Hematopoietic Stem Cell Transplantation
  • Hepatic cGVHD
  • Belumosudil
  • Ruxolitinib
03

In context

Lead sponsor

First Affiliated Hospital of Zhejiang University is the lead sponsor of 264 studies on the registry; 145 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 12 years at time of signing .
  2. Received hematopoietic stem cell transplantation.
  3. Meets 2014 NIH consensus criteria for hepatic cGVHD (≥1 of: total > 2×, ALP > 2×ULN, > 2×ULN, or liver -proven cGVHD-related injury), after excluding other causes.
  4. performance status ≤ 2.
  5. Able to take oral medication.
  6. ≥ 6 months.
  7. Adequate organ function: ≥ 1.0×10⁹/L, ≥ 50×10⁹/L, ≥ 30 mL/min.
  8. Female patients of have negative pregnancy test and agree to effective during study and for 6 months after last dose; male patients agree to same.
  9. Willing and able to provide written informed consent and comply with study requirements.
  10. Cohort 1 (-): Progressive disease on stable steroids (1 mg/kg/day) within 1-2 weeks prior to screening, or persistent cGVHD without improvement after ≥4 weeks of prednisone (or equivalent) > 0.5 mg/kg/day. (Prior aGVHD JAK inhibitor use allowed if stopped ≥8 weeks.).
  11. Cohort 2 (Breakthrough hepatic cGVHD): Patients on stable (≥2 weeks) ruxolitinib or belumosudil monotherapy for non-hepatic cGVHD for ≥4 weeks, who develop new-onset hepatic cGVHD or experience no response or progression on current therapy for hepatic cGVHD, not attributable to other etiologies (e.g., viral hepatitis, drug-induced liver injury, biliary obstruction, iron overload, alcoholic liver disease), with no prior exposure to the alternative study agent.

Exclusion criteria

Exclusion Criteria:

  1. Receiving newly initiated systemic cGVHD therapy other than and calcineurin inhibitors (CNIs); corticosteroids and CNIs must be on a stable regimen for ≥2 weeks prior to screening.
  2. Uncontrolled active acute (≥ grade 2).
  3. Active viral hepatitis or infection.
  4. Liver function abnormalities due to other causes, including but not limited to drug-induced liver injury, hepatitis, alcoholic liver disease, biliary obstruction, VOD/SOS, iron overload, Gilbert's syndrome, or hemolysis.
  5. Severe cardiovascular or cerebrovascular disease, including but not limited to: class ≥3, uncontrolled hypertension, severe arrhythmia, or myocardial infarction/stroke within 6 months.
  6. Respiratory failure requiring mechanical ventilation, resting pulse oxygen saturation \<90%, or severe/uncontrolled pulmonary cGVHD or other respiratory disease that may significantly affect patient safety or study assessment, per investigator judgment.
  7. Inability to take oral medication, severe gastrointestinal dysfunction ( v5.0 ≥ grade 3), severe GI cGVHD requiring parenteral nutrition, daily diarrhea >1 L, or any other condition significantly affecting GI absorption.
  8. Significant neurological or psychiatric history (including epilepsy or dementia) that makes the subject unsuitable for participation.
  9. primary or PTLD.
  10. History of other malignancies, except cured and fully resected basal or squamous cell skin carcinoma, surgically cured cervical carcinoma in situ, resected ductal carcinoma in situ of the breast, prostate cancer (Gleason \<6 with stable PSA >12 months), or other malignancies with no evidence of recurrence after curative treatment.
  11. abnormality: >450 ms (male) or >470 ms (female) at screening.
  12. Known alcohol or drug dependence.
  13. Pregnant or breastfeeding women.
  14. Allergy to study drug or its .
  15. Any other condition that may affect patient safety or compliance, per investigator judgment.
  16. Cohort 1: Prior cGVHD treatment with JAK inhibitors (e.g., ruxolitinib) or ROCK2 inhibitors (e.g., belumosudil); receipt of other therapy within 30 days prior to randomization, or \<5 half-lives since last investigational product.
  17. Cohort 2: Patients with prior exposure to both ruxolitinib and belumosudil.
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
170 participants (estimated)

Study arms

  • Active comparator
    Ruxolitinib Group

    Participants assigned to this arm will receive ruxolitinib administered orally at the standard approved dose and schedule for the treatment of steroid-refractory hepatic chronic graft-versus-host disease (cGVHD).

    Drug: Ruxolitinib treatment

  • Experimental
    Belumosudil Group

    Participants assigned to this arm will receive belumosudil administered orally at the standard approved dose and schedule for the treatment of steroid-refractory hepatic chronic graft-versus-host disease (cGVHD).

    Drug: Belumosudil treatment

  • Other
    Belumosudil Switch to Ruxolitinib Group

    Participants with breakthrough hepatic cGVHD on stable belumosudil therapy for non-hepatic cGVHD who develop new-onset hepatic cGVHD or have no response/progression on belumosudil, not attributable to other etiologies, and with no prior ruxolitinib exposure, will discontinue belumosudil and cross over to ruxolitinib.

    Drug: Belumosudil Switch to Ruxolitinib

  • Other
    Ruxolitinib Switch to Belumosudil Group

    Participants with breakthrough hepatic cGVHD on stable ruxolitinib therapy for non-hepatic cGVHD who develop new-onset hepatic cGVHD or have no response/progression on ruxolitinib, not attributable to other etiologies, and with no prior belumosudil exposure, will discontinue ruxolitinib and cross over to belumosudil.

    Drug: Ruxolitinib Switch to Belumosudil

Interventions

  • DrugRuxolitinib treatment

    Ruxolitinib treatment

  • DrugBelumosudil treatment

    Belumosudil treatment

  • DrugBelumosudil Switch to Ruxolitinib

    Belumosudil Switch to Ruxolitinib

  • DrugRuxolitinib Switch to Belumosudil

    Ruxolitinib Switch to Belumosudil

06

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR) for Hepatic cGVHD at Week 24

    Time frame: at Week 24 after treatment

Secondary outcomes

  1. Best overall response (BOR)

    Time frame: Assessed continuously throughout the study from the date of randomization,up to 24 weeks after treatment

  2. Duration of response (DOR)

    Time frame: From first response to progression/death, whichever came first, assessed up to 2 years after the date of randomization

  3. Incidence of adverse events (AEs)

    Time frame: Continuous monitoring from first dose to 30 days after last dose

  4. Quality of life (QoL) score

    Time frame: Assessed at baseline, Week 12, Week 24, and end of treatment

  5. Overall survival (OS)

    Time frame: From date of randomization until the date of death from any cause, whichever came first, assessed up to 2 years after the date of randomization.

  6. Failure-free survival (FFS)

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years after the date of randomization.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, Palmer J, Weisdorf D, Treister NS, Cheng GS, Kerr H, Stratton P, Duarte RF, McDonald GB, Inamoto Y, Vigorito A, Arai S, Datiles MB, Jacobsohn D, Heller T, Kitko CL, Mitchell SA, Martin PJ, Shulman H, Wu RS, Cutler CS, Vogelsang GB, Lee SJ, Pavletic SZ, Flowers ME. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant. 2015 Mar;21(3):389-401.e1. doi: 10.1016/j.bbmt.2014.12.001. Epub 2014 Dec 18. PubMed 25529383 ↗
  • Hall K, Lazaryan A, van der Laan M, Lee C, Logan AC, Gruber S, Kabadi S, Khan I, Nicholls C, Rota L, Nikai E, Ponomareva E, Koumas A, Waller EK. Efficacy and safety of belumosudil as compared with best available therapy for the treatment of cGVHD in the United States. Blood Adv. 2026 Feb 10;10(3):682-693. doi: 10.1182/bloodadvances.2025015832. PubMed 40875591 ↗
  • Lee SJ, Pavletic S, Blazar BR, Yao Y, Ji R, Marshall K, Cutler C; KD025-208 and ROCKstar Study Investigators. Belumosudil for Chronic Graft-Versus-Host Disease: Analysis of Long-Term Results from the KD025-208 and ROCKstar Studies. Transplant Cell Ther. 2025 Jul;31(7):434.e1-434.e10. doi: 10.1016/j.jtct.2025.04.020. Epub 2025 May 1. PubMed 40318736 ↗
  • Ibrahimova A, Bidgoli A, Ashraf A, Krogman A, Klink G, Teusink-Cross A, Schoettler ML, Davies SM, Khandelwal P. Real world experience using belumosudil for treatment of chronic graft versus host disease in children and young adults. Bone Marrow Transplant. 2026 Apr;61(4):487-489. doi: 10.1038/s41409-025-02795-9. Epub 2026 Jan 21. No abstract available. PubMed 41566004 ↗
  • Nalkurthi C, Schroder WA, Melino M, Irvine KM, Nyuydzefe M, Chen W, Liu J, Teng MWL, Hill GR, Bertolino P, Blazar BR, Miller GC, Clouston AD, Zanin-Zhorov A, MacDonald KPA. ROCK2 inhibition attenuates profibrogenic immune cell function to reverse thioacetamide-induced liver fibrosis. JHEP Rep. 2021 Oct 6;4(1):100386. doi: 10.1016/j.jhepr.2021.100386. eCollection 2022 Jan. PubMed 34917911 ↗
  • Modi B, Ngo D, Chen J, Yang D, Shan H, Sandhu K, Rashid N, Amanam I, Otoukesh S, Nakamura R, Ali H, Salhotra A. Belumosudil for the treatment of chronic graft-versus-host disease: a single center real-world experience. Bone Marrow Transplant. 2025 Apr;60(4):555-557. doi: 10.1038/s41409-024-02498-7. Epub 2025 Feb 4. No abstract available. PubMed 39905130 ↗
  • Michonneau D, Malard F, Le Grand S, Magro L, D'Aveni M, Tudesq JJ, Villate A, Meunier M, Maillard N, Castilla-Llorente C, Marcais A, Cabrera Q, Huynh A, Menard AL, Forcade E, Labussiere-Wallet H, Raus N, Loschi M. Efficacy and safety of belumosudil for treatment of cGVHD: multicenter retrospective analysis of the French cohort of the compassionate use program, on behalf of the French Society of Bone Marrow Transplantation and Cellular Therapy. Bone Marrow Transplant. 2025 Jun;60(6):779-786. doi: 10.1038/s41409-025-02554-w. Epub 2025 Apr 1. PubMed 40169928 ↗
  • Jagasia M, Lazaryan A, Bachier CR, Salhotra A, Weisdorf DJ, Zoghi B, Essell J, Green L, Schueller O, Patel J, Zanin-Zhorov A, Weiss JM, Yang Z, Eiznhamer D, Aggarwal SK, Blazar BR, Lee SJ. ROCK2 Inhibition With Belumosudil (KD025) for the Treatment of Chronic Graft-Versus-Host Disease. J Clin Oncol. 2021 Jun 10;39(17):1888-1898. doi: 10.1200/JCO.20.02754. Epub 2021 Apr 20. PubMed 33877856 ↗
  • Inamoto Y, Kato K, Kawakita T, Onishi Y, Matsuoka KI, Shiratori S, Ikegame K, Hiramoto N, Toyosaki M, Katayama Y, Murayama S, Sasagawa Y, Maeda Y, Hatake K, Teshima T. An open-label study of belumosudil, a selective ROCK2 inhibitor, as second or subsequent line of therapy for steroid-dependent/steroid-resistant chronic GVHD. Am J Hematol. 2024 Oct;99(10):1917-1926. doi: 10.1002/ajh.27424. Epub 2024 Jun 27. PubMed 38934629 ↗
  • Cutler C, Lee SJ, Arai S, Rotta M, Zoghi B, Lazaryan A, Ramakrishnan A, DeFilipp Z, Salhotra A, Chai-Ho W, Mehta R, Wang T, Arora M, Pusic I, Saad A, Shah NN, Abhyankar S, Bachier C, Galvin J, Im A, Langston A, Liesveld J, Juckett M, Logan A, Schachter L, Alavi A, Howard D, Waksal HW, Ryan J, Eiznhamer D, Aggarwal SK, Ieyoub J, Schueller O, Green L, Yang Z, Krenz H, Jagasia M, Blazar BR, Pavletic S. Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study. Blood. 2021 Dec 2;138(22):2278-2289. doi: 10.1182/blood.2021012021. PubMed 34265047 ↗
  • Zeiser R, Russo D, Ram R, Hashmi SK, Chakraverty R, Middeke JM, Musso M, Giebel S, Uzay A, Langmuir P, Hamad N, Burock K, Gowda M, Stefanelli T, Lee SJ, Teshima T, Locatelli F. Ruxolitinib in Patients With Corticosteroid-Refractory or Corticosteroid-Dependent Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of the Phase III REACH3 Study. J Clin Oncol. 2025 Aug 10;43(23):2566-2571. doi: 10.1200/JCO-24-02477. Epub 2025 Jun 25. PubMed 40561385 ↗
  • Zeiser R, Polverelli N, Ram R, Hashmi SK, Chakraverty R, Middeke JM, Musso M, Giebel S, Uzay A, Langmuir P, Hollaender N, Gowda M, Stefanelli T, Lee SJ, Teshima T, Locatelli F; REACH3 Investigators. Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease. N Engl J Med. 2021 Jul 15;385(3):228-238. doi: 10.1056/NEJMoa2033122. PubMed 34260836 ↗
  • Zeiser R, Lee SJ. Three US Food and Drug Administration-approved therapies for chronic GVHD. Blood. 2022 Mar 17;139(11):1642-1645. doi: 10.1182/blood.2021014448. PubMed 35081254 ↗
  • Hematopoietic Stem Cell Application Group, Chinese Society of Hematology, Chinese Medical Association. [Chinese expert consensus on the diagnosis and treatment of chronic graft-versus-host disease (2024)]. Zhonghua Xue Ye Xue Za Zhi. 2024 Aug 14;45(8):713-726. doi: 10.3760/cma.j.cn121090-20240611-00217. Chinese. PubMed 39307718 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2026 (actual). Primary completion is estimated for Apr 2030, 42 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 25, 2026
First posted
Aug 31, 2026
StartActual
Oct 1, 2026
Primary completionEst.
Apr 1, 2030
CompletionEst.
Dec 31, 2030
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: date precision
1 update, last Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Minor edits only
    + 1 other change: date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07794514
Responsible party
Yanmin Zhao (Vice Director, Bone Marrow Transplantation Center, the First Affiliated Hospital, School of Medicine, Zhejiang University, First Affiliated Hospital of Zhejiang University) — Principal investigator
First posted
Aug 31, 2026
Start date
Oct 1, 2026
Primary completion
Apr 1, 2030 (estimated)
Completion
Dec 31, 2030 (estimated)
Last update
Nov 17, 2026

Study contacts

Fei Gao
Contact
gf0906@zju.edu.cn
+86 19857035073

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion